It’s time for some fun.
For the past 20 years or so, I have made it my mission to hunt for some of the most promising private biotechnologies in the industry to be part of an annual report I now call Endpoints 11. And we’re back on track for next big round of prizes.
Every now and then I get questions about what are the basic criteria for inclusion. It’s easy. If you’re looking to do great things in drug development, break new ground, go to the well-known next level with an outstanding team, promising science and supporters – or promise to make a colossal sound if you fail – then you should make a short list.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.